• Home
  • NEW DAY MEDICINE
  • 9 (71) 2024
  • 32 -9 (71) 2024 - Ergashov M.M., Zhurayev B.R. - PROCALCITONIN BIOMARKER AS A PROGNOSTIC FACTOR OF COVID-19 ANTIBACTERIAL THERAPY

32 -9 (71) 2024 - Ergashov M.M., Zhurayev B.R. - PROCALCITONIN BIOMARKER AS A PROGNOSTIC FACTOR OF COVID-19 ANTIBACTERIAL THERAPY

PROCALCITONIN BIOMARKER AS A PROGNOSTIC FACTOR OF COVID-19 ANTIBACTERIAL THERAPY

Ergashov M.M. - Bukhara State Medical Institute named after Abu Ali ibn Sino

Zhurayev B.R. - Bukhara State Medical Institute named after Abu Ali ibn Sino

Resume

The value of procalcitonin (PCT) has been studied as a biomarker for assessing: the risk of bacterial infection, disease progression, timely administration of antibacterial drugs and the duration of the course of antibacterial therapy. PCT synthesis: in healthy people, PCT synthesis occurs in the C cells of the thyroid gland, where it is completely converted into the active form – calcitonin. Due to its complete transformation, PCT is not detected in the blood of healthy people and its amount does not exceed 0.05 ng/ml. When lipopolysaccharide (LPS) of a microorganism, which is an endotoxin, enters the human blood, the process of PCT synthesis is activated. Within 2-6 hours, its blood level rises rapidly several times.

Keywords: SARS-CoV-2, pneumonia, C-reactive protein, procalcitonin, cytokines, LPS, biomarkers, antibiotics, antibacterial therapy, prognosis.

First page

163

Last page

168

For citation:Ergashov M.M., Zhurayev B.R. - PROCALCITONIN BIOMARKER AS A PROGNOSTIC FACTOR OF COVID-19 ANTIBACTERIAL THERAPY//New Day in Medicine 9(71)2024 163-168 https://newdayworldmedicine.com/en/new_day_medicine/9-71-2024

List of References

  1. Lu H., Stratton C.W., Tang Y.-W.: Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. //J. Med. Virol., 2020;92:401-402.
  2. Oblokulov, A. R., Niyozov, G.E. (2020) Clinical and epidemiological characteristics of patients with COVID-19. //International Journal of Pharmaceutical Research; 2020;12(4):3749-3752.
  3. Oblokulov, A.R., Husenova, Z. Z., Ergashev, M. M. (2021). Procalcitonin as an indicator of antibacterial therapy in covid-19. //Annals of the Romanian Society for Cell Biology, 2021; 5220-5224.
  4. Cao Y., Liu X., Xiong L. et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. //J. Med. Virol., 2020; doi: 10.1002/jmv.25 822.
  5. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. //Crit Care Med 2006;34(7):1996-2003.
  6. Kutz A, Briel M, Christ-Crain M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. //Critical Care (London, England) 2015;19(1):74.
  7. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. //Cochrane Database Syst Rev. 2017;10:CD007498.
  8. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-
  9. Oblokulov A.R., Husenova Z. Z., Ergashev M.M. (2021). Clinical and epidemiological characteristics of patients with SARS-Cov-2, COVID 19 infection. //New day in medicine Bukhara, 2021;2(34/3):270-273.
  10. Heesom L, Rehnberg L, Nasim-Mohi M, Jackson AIR, Celinski M, Dushianthan A, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. //J Glob Antimicrob Resist. 2020;22:782-4.
  11. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. //BMJ. 2020;368:m1091.
  12. Oblokulov Abdurashid Rakhimovich, Kholov Uktam Asadovich, Niyozov Gulom Eshmuradovich, Ergashov Maqsud Muzaffarovich, Khusenova Zilola Zakhirovna. (2021). Extrapulmonal manifestations of COVID – 19. //“Infection, immunity and pharmacology –scientific and practical journal - Tashkent, 2021;1/21:62-66.
  13. Guan, W., Ni, Z., Hu, Y. et al. Clinical characteristics of 2019 novel coronavirus infection in China //N Engl J Med. 2020;382(18):1708-1720.
  14. Williams E.J. et al. (2020) Routine measurement of serum procalcitonin allows antibiotics to be safely withheld in patients admitted to hospital with SARS-CoV-2 infection. medRxiv. doi. org/10.1101/2020.06.29.20136572.
  15. Niyazov G.E., Oblokulov A.R., Pondina A.I. et al. (2020) Clinical and epidemiological characteristics of COVID-19 patients //New Day in Medicine. 2020;4(32):110-115.
  16. Meisner M. Procalcitonin – biochemistry and clinical diagnosis. //Bremen: UNI-MED; 2010; 128 p.
  17. Wolfisberg S., Gregoriano C., Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. //Crit. Rev. Clin. Lab. Sci., 2022;59(1):54-65. doi: 10.1080/10408363.2021.1975637.
  18. Zhou F., Yu T. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. //Lancet, 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
  19. Oblokulov A.R., Musaeva D.M., Elmuradova A.A. (2020) Clinical and epidemiological characteristics of the new coronavirus infection (COVID-19). //New Day in Medicine. 2020;2 (30/2):110-115.
  20. España P., Capelastegui A. et al. Population Study of Pneumonia (PSoP) Group. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia //Eur. J. Clin. Microbiol. Infect. Dis. – 2012;31(12):3397-3405. doi:10.1007/s10096-012-1708-5.

    file

    download